Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program | BioSpace

[ad_1] – Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 – – Company’s intellectual property portfolio now…

Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions

[ad_1] Zealand Pharma Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions…